ABOS — Acumen Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $189.25m
- -$23.62m
- 25
- 41
- 57
- 36
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.7 | 1.44 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 9.5 | 9.35 | 19.6 | 45.2 | 61.1 |
Operating Profit | -7.8 | -7.91 | -19.6 | -45.2 | -61.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -7.91 | -7.33 | -101 | -42.9 | -52.4 |
Net Income After Taxes | -7.91 | -7.33 | -101 | -42.9 | -52.4 |
Net Income Before Extraordinary Items | |||||
Net Income | -7.91 | -7.33 | -101 | -42.9 | -52.4 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -7.69 | -7.33 | -101 | -42.9 | -52.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.199 | -0.19 | -5.02 | -1.06 | -1.08 |
Dividends per Share |